A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 11, 2016, Pages 1860-1867

  Wei, Lai ^a   Zhang, Mingxiang ^b   Xu, Min ^c   Chuang, Wan Long ^d   Lu, Wei ^e   Xie, Wen ^f   Jia, Zhansheng ^g   Gong, Guozhong ^h   Li, Yueqi ⁱ   Bae, Si Hyun ^j   Yang, Yong Feng ^k   Xie, Qing ^l   Lin, Shumei ^m   Chen, Xinyue ⁿ   Niu, Junqi ^o   Jia, Jidong ^p   Garimella, Tushar ^q   Torbeyns, Anne ^q   McPhee, Fiona ^q   Treitel, Michelle ^q   Yin, Philip D ^q   Mo, Ling ^q   more..

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Department of Clinical Laboratory Sixth Peoples' Hospital of Shenyang   (China)

^c Guangzhou Eighth People's Hospital   (China)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e Tianjin Second People s Hospital   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^h CENTRAL SOUTH UNIVERSITY   (China)

ⁱ BEIJING 302 HOSPITAL   (China)

^j The Catholic University of Korea   (South Korea)

^k Nanjing Second Hospital   (China)

^l SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^m THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

ⁿ CAPITAL MEDICAL UNIVERSITY   (China)

^o THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^p CAPITAL MEDICAL UNIVERSITY   (China)

^q BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

asunaprevir; daclatasvir; efficacy; hepatitis C; safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASUNAPREVIR; BILIRUBIN; DACLATASVIR; HEMOGLOBIN; LACTATE DEHYDROGENASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRIACYLGLYCEROL LIPASE;

ABNORMAL LABORATORY RESULT; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASIAN; BILIRUBIN BLOOD LEVEL; CHINA; CHINESE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE; GENOTYPE; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; HYPERURICEMIA; IL28B GENE; KOREA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; TAIWAN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; MULTICENTER STUDY;

EID: 84996520684     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13379     Document Type: Article

References (25)

1. World Health Organization. Hepatitis C key facts. WHO factsheet No 164. July, 2015. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed July, 2015.
2. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014–1018.
3. Manns MP, von Hahn T. Novel therapies for hepatitis C—one pill fits all? Nat. Rev. Drug Discov. 2013; 12: 595–610.
4. Melia MT, Muir AJ, McCone J et al. Racial differences in hepatitis C treatment eligibility. Hepatology 2011; 54: 70–78.
5. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view. Accessed April, 2015.
6. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J. Hepatol. 2015; 63: 199–236.
7. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr. Opin. Virol. 2013; 3: 514–520.
8. McPhee F, Sheaffer AK, Friborg J et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob. Agents Chemother. 2012; 56: 5387–5396.
9. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int. 2011; 31 (suppl 2): 1–3.
10. Sievert W, Altraif I, Razavi HA et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011; 31 (suppl 2): 61–80.
11. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol. 2009; 50: 1142–1154.
12. Rao H, Wei L, Lopez-Talavera JC et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J. Gastroenterol. Hepatol. 2014; 29: 545–553.
13. Lee MH, Yang HI, Lu SN et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J. Clin. Oncol. 2010; 28: 4587–4593.
14. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083–2091.
15. Manns M, Pol S, Jacobson IM et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597–1605.
16. Kao JH, Jensen DM, Manns MP et al. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2015 published online 24 Jan 2016. DOI: 10.1111/liv.13049.
17. McPhee F, Suzuki Y, Toyota J et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv. Ther. 2015; 32: 637–649.
18. Poordad F, Schiff ER, Vierling JM et al. Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant reccurrence: phase 3 ALLY-1 study. J. Hepatol. 2015; 62: S261 [Abstract L08].
19. Muir AJ, Poordad F, Lalezari J et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015; 313: 1736–1744.
20. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013; 368: 1878–1887.
21. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417–2428.
22. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207–1217.
23. Lok AS, Gardiner DF, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012; 366: 216–224.
24. Lok AS, Gardiner DF, Hezode C et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J. Hepatol. 2014; 60: 490–499.
25. Bronowicki JP, Pol S, Thuluvath PJ et al. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antivir. Ther. 2013; 18: 885–893.